Thèse D.GATEFF

188 BERGER K, BRETELER MMB, HELMER C, et coll. Prognosis with Parkinson s disease in Europe : a
collaborative sutdy of population-based cohorts. Neurology 2000 ; 54 (suppl5) : 24-27
189 DE RIJK MC, LAUNER LJ, BERGER K et coll. Op. cit.
190 TISON F, DARTIGUES JF, DUBES F et coll. Op. cit.
191 Ibid.
192 Ibid.
193 BRYSON HM, MILNE RJ, CHRISP P. Selegiline : an appraisal of it pharmacoeconomics and quality of life
benefits in Parkinson s disease. Pharmacoeconomics 1992 ; 2 : 118-136
194 LE PEN C, WAIT S, MOUTARD-MARTIN F et coll. Cost of illness and disease severity in a cohort of
French patients with Parkinson s disease. Pharmacoeconomics 1999 ; 16 56-69
195 ZAGNOLI F. Op. cit P162
196 DEFEBVRE L, VERIN M. Op. cit p177
197 DOROZ P. Op. cit.
198 DEFEBVRE L, VERIN M. Op.cit p151-172
199 199 LANDRY Y, Op. cit. P359
200 RASCOL O, BROOKS DJ, KORCZYN AD et coll. A five year study of incidence of dyskinésia in patients
with early pParkinson s disease who were treated with ropinirole or levodopa. N Engl J M 2000 ; 342 : 1484 -
1491
201 ZAGNOLI F. Op. cit. P78
202 HOLLOWAY et coll. Parkinson study group. Pramipexole versus levodopa as initial treatement for Parkinson
disease a 4 year randomized control trial. Arch Neurol 2004 ; 61 : 1044-1053
203 ZAGNOLI F. Op. cit. P78
204 Ibid.
205 Ibid
206 Ibid. P77
207 MYLLYLÄ VV, SOTANIEMI KA, VÜORINGEN JA et coll. Selegiline as initial treatment in de novo
parkinsonian patients. Neurology 1992 ; 42 : 339-343
208 GOLBE LI. Long term efficacy and safety of deprenyl (selegiline) in advanced Parkinson disease. Neurology
1989 ; 39 : 1109 1111.
209 RINNE UK, LARSEN JP, SIDEN A et coll. Entocapone enhance the restponse to levodopa in parkinsonian
patients with motor fluctuation. Neurology 1998 ; 51 : 1309-1314
210 KURTH MC, ADLER CH, HILAIRE MS et coll. Tolcapone improved motor function and reduces levodopa
requirement in patients with Parkinson s disease experiencing motor fluctuation : a multicenter double-blind
randomized placebo-controlled trial. Neurology 1997 ; 48 : 81-87
211 SCHWABS RS, ENGLAND ACJ, POSKANZER DC et coll. Amantadine in the treatment of Parkinson s
disease. J Am Med Assoc 1969 ; 208 : 1168-1170.
212 BLANCHET PJ, KONITSIOTIS S, CHASE TN. Amantadine reduces Levodopa-induced dyskinesias in
parkinsonian monkeys. Mov Disord 1998 ; 13 : 798-802
213 GOETZ CG. New lessons from old drugs : amantadine and Parkinson disease. Neurology 1998 ; 50 : 1211-
1212
214 DURIF F, DEBILLY B, GALITZKY M et coll. Clozapine improves dyskinesias in Parkinson s disease : a
double-blind placebo controlled study. Neurology 2004 ; 62 : 381-388
215 RASCOL O, BROOKS DJ, KORCZYN AD et coll. A five year study of incidence of dyskinésia in patients
with early pParkinson s disease who were treated with ropinirole or levodopa. N Engl J M 2000 ; 342 : 1484 -
1491
216 ANAES Conférence de consensus du 3 mars 200. La Maladie de Parkinson : critères diagnostics et
thérapeutiques. Texte de recommandation.
217 DEFEBVRE L., VERIN M. Op. cit P173-189
218 ZAGNOLI F. Op. cit. P83-93
219 DEFER GL, WIDNER H, MARIE RM et coll. Core assessment program for surgical interventional therapies
in Parkinson s disease (CAPSIT-PD). Mov Disord 1999 ; 14 : 572-584
220 BLOND S, TOUZET G, KRYSTKOWIAK P et coll. Le traitement neurochirurgical de la maladie de
Parkinson : quelle technique retenir ? Rev Neurol (Paris) 2000 ; 156(suppl 2 Pt 2) : 257 : 269.
221 FRAIX V, HOUETO JL, LAGRANGE C et coll. Résultats cliniques et économiques de la stimulation du
noyau sous thalamique dans la maladie de Pakinson. Rev Neurol (Paris) 2005 ; 161 (suppl 1) : 15-16
222 DEFEBVRE L, VERIN M. Op. cit p177
223 ZAGNOLI F. Op. cit. P87
224 VOLKMANN J, HERZOG J, KOPPER F et coll. Introduction to the programming of deep brain stimulators.
Mov Disord 2002 ; 17 (suppl 3) : S181-187.
261